NCUEarningsglobenewswire

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Sentiment:Negative (30)

Summary

First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 20, 2025 by globenewswire